Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland

Aj, McKnight; Shaw, A.; Ce, Goldsmith; Clarke, Lena; Bc, Millar; McCaughan, J.; Elborn, J. Stuart; Reid, A.; Je, Moore

doi:10.1080/09674845.2005.11978067

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MICs for ciprofloxacin and levofloxacin against the CF isolates tested in this study are consistent with those found in other studies, which reported that the activity of levofloxacin was superior or equivalent to that of ciprofloxacin against isolates of P. aeruginosa, B. cepacia complex, S. maltophilia, A. xylosoxidans, MSSA, and MRSA from CF and non-CF patients (6,16,18,21,27,40). Although levofloxacin and ciprofloxacin had similar MICs against P. aeruginosa (MIC 90 ϭ 8 g/ml for both drugs), it was previously shown that resistant mutants of nonmucoid P. aeruginosa CF isolates could be more readily selected with ciprofloxacin in vitro (15).…”

Section: Discussionsupporting

confidence: 81%

In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis

King

Lomovskaya

Griffith

et al. 2010

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The inhalational administration of antibiotics can provide high concentrations locally in the lungs of cystic fibrosis patients and, thus, can be useful for the treatment of chronic bacterial infections. The present study evaluated the in vitro activities of levofloxacin, ciprofloxacin, tobramycin, amikacin, and aztreonam against clinical isolates of Pseudomonas aeruginosa, Burkholderia cepacia complex, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and Staphylococcus aureus from cystic fibrosis patients. Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC 90 s ranging from 8 to 32 g/ml. Levofloxacin was more potent than the aminoglycosides and aztreonam against P. aeruginosa biofilms. Time-kill assays with drug concentrations achievable in sputum following aerosol administration showed that levofloxacin had the most rapid rate of killing among mucoid and nonmucoid isolates of P. aeruginosa. In contrast to tobramycin, the bactericidal activity of levofloxacin was not affected by sputum from cystic fibrosis patients. The results of the study show that the high concentrations of levofloxacin readily achievable in the lung following aerosol delivery may be useful for the management of pulmonary infections in patients with cystic fibrosis.

show abstract

Section: Discussionsupporting

confidence: 81%

In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis

King

Lomovskaya

Griffith

et al. 2010

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…According to the results, trimethoprim-sulfamethoxazole was the most active antibiotic (all isolates were susceptible), whereas levofloxacin demonstrated good activity (82% of isolates were susceptible). In Northern Ireland, Mcknight et al [25] verified the in vitro antibiotic susceptibility (Etest) of levofloxacin against 10 S. maltophilia isolates obtained from adult and pediatric CF patients. The results indicated again that levofloxacin exhibited excellent inhibitory activity against this microorganism.…”

Section: Discussionmentioning

confidence: 97%

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance

Goncalves-Vidigal

Große-Onnebrink

Mellies

et al. 2011

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis

Bostanghadiri,

Sholeh,

Navidifar

et al. 2024

Ann Clin Microbiol Antimicrob

View full text Add to dashboard Cite

Introduction Infections caused by Stenotrophomonas maltophilia are clinically important due to its intrinsic resistance to a broad range of antibiotics. Therefore, selecting the most appropriate antibiotic to treat S. maltophilia infection is a major challenge. Aim The current meta-analysis aimed to investigate the global prevalence of antibiotic resistance among S. maltophilia isolates to the develop more effective therapeutic strategies. Method A systematic literature search was performed using the appropriate search syntax after searching Pubmed, Embase, Web of Science and Scopus databases (May 2023). Statistical analysis was performed using Pooled and the random effects model in R and the metafor package. A total of 11,438 articles were retrieved. After a thorough evaluation, 289 studies were finally eligible for inclusion in this systematic review and meta-analysis. Result Present analysis indicated that the highest incidences of resistance were associated with doripenem (97%), cefoxitin (96%), imipenem and cefuroxime (95%), ampicillin (94%), ceftriaxone (92%), aztreonam (91%) and meropenem (90%) which resistance to Carbapenems is intrinsic. The lowest resistance rates were documented for minocycline (3%), cefiderocol (4%). The global resistance rate to TMP-SMX remained constant in two periods before and after 2010 (14.4% vs. 14.6%). A significant increase in resistance to tigecycline and ceftolozane/tazobactam was observed before and after 2010. Conclusions Minocycline and cefiderocol can be considered the preferred treatment options due to low resistance rates, although regional differences in resistance rates to other antibiotics should be considered. The low global prevalence of resistance to TMP-SMX as a first-line treatment for S. maltophilia suggests that it remains an effective treatment option.

show abstract

Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland

Cited by 4 publications

References 0 publications

In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis

In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance

Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis

Contact Info

Product

Resources

About